## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.4% below STRENGTH zone (4.0-10.0%); PEG 33.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. BAX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!**
- Source: KTSM 9 News | 20251209T120730 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors who purchased securities between February 23, 2022, and October 29, 2025. The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in its Novum LVP medical devices which caused serious patient harm and posed risks to sales. Investors who suffered losses have until December 15, 2025, to request to be appointed as lead plaintiff.

**2. Pomerantz LLP Notifies Shareholders of Class Action Lawsuit Against Baxter International, Inc. – BAX**
- Source: WATE 6 On Your Side | 20251209T120754 | Neutral | Relevance: 99%
-  Pomerantz LLP has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) concerning alleged securities fraud. The lawsuit stems from Baxter's voluntary and temporary pause of shipments for its Novum LVP medical device, which caused a significant drop in its stock price. Investors who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

**3. Pomerantz LLP Notifies Shareholders of Class Action Filing Against Baxter International, Inc. – BAX**
- Source: SiouxlandProud | 20251208T120825 | Neutral | Relevance: 99%
-  Pomerantz LLP has filed a class action lawsuit against Baxter International, Inc. (NYSE: BAX) on behalf of investors alleging securities fraud or unlawful business practices. The lawsuit comes after Baxter announced a voluntary pause on shipments of its Novum LVP medical device, causing its stock price to fall significantly. Investors who purchased Baxter securities during the Class Period have until December 15, 2025, to seek appointment as Lead Plaintiff.

**4. Securities Fraud Class Action Filed Against Baxter International, Inc. (BAX) - Levi & Korsinsky Reminds Investors of December 15, 2025**
- Source: CW39 Houston | 20251207T160755 | Neutral | Relevance: 99%
-  Levi & Korsinsky, LLP has filed a securities fraud class action lawsuit against Baxter International, Inc. (NYSE:BAX) on behalf of investors who suffered losses between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter made false and misleading statements regarding systemic defects in its Novum LVP product, which caused widespread malfunctions, patient injuries, and deaths. Investors are encouraged to contact Levi & Korsinsky to learn about their rights to seek recovery by the December 15, 2025 deadline.

**5. BAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!**
- Source: KETK.com | 20251207T120829 | Neutral | Relevance: 99%
-  Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) and some of its officers. The lawsuit, filed on behalf of investors who purchased Baxter securities between February 23, 2022, and October 29, 2025, alleges that the company misled investors regarding defects in its Novum LVP products. Investors who suffered losses have until December 15, 2025, to request to be appointed lead plaintiff.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 33.7x requires aggressive growth execution.
2. Elevated short interest (8.6%): bears positioning against stock.
3. Long-term trend broken: trading 32.3% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 33.66 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.3B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 8.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 33.66 |
| Forward P/E | 7.9 |
| Current P/E | 7.7 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.2% to -3.4% (-4.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.68x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.43% (CS: 31) | Weak |
| RSI_14 | 39.6 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 0.893x | Below |
| vs SMA200 | 0.677x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.16
- **Stop Loss:** $17.04 (6.2% risk)
- **Target:** $19.28 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 267
- **Position Value:** $4,848.72
- **Portfolio %:** 4.85%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*